Lek Pharmaceuticals d.d

Summary

Organization: Lek Pharmaceuticals d.d
Country: Slovenia

Top Publications

  1. ncbi The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems
    M D Tricklebank
    Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Essex, UK
    Behav Brain Res 73:15-7. 1996
  2. ncbi Platelet glycoprotein IIIa gene expression in normal and malignant megakaryopoiesis
    Tanja Ficko
    Lek Pharmaceuticals d d, Biopharmaceuticals, Kolodvorska 27, 1234, Menge, Slovenia
    Ann Hematol 87:131-7. 2008
  3. ncbi Biosimilar somatropin: myths and facts
    W Hoppe
    Sandoz International GmbH, Holzkirchen, Germany
    Horm Res 69:29-30. 2008
  4. pmc Improved determination of plasmid copy number using quantitative real-time PCR for monitoring fermentation processes
    Mihaela Skulj
    Lek Pharmaceuticals d, d, a Sandoz Company, Verovskova 57, SI 1526 Ljubljana, Slovenia
    Microb Cell Fact 7:6. 2008
  5. ncbi Optimization of UDP-N-acetylmuramic acid synthesis
    J Humljan
    Drug Discovery Department, Lek Pharmaceuticals, Verovikova 57, 1526 Ljubljana, Slovenia
    Pharmazie 63:102-6. 2008
  6. doi Identification of the heparin-binding domain of TNF-alpha and its use for efficient TNF-alpha purification by heparin-Sepharose affinity chromatography
    Maja Kenig
    Lek Pharmaceuticals d d, Verovskova 57, SI 1526 Ljubljana, Slovenia
    J Chromatogr B Analyt Technol Biomed Life Sci 867:119-25. 2008
  7. doi Expression of oestrogen receptor alpha during development of the skeleton in mice fetuses: immunohistochemical study
    E Lovsin Barle
    Institute of Anatomy, Histology and Embryology, Faculty of Veterinary Medicine, University of Ljubljana, Gerbiceva 60, 1000 Ljubljana, Slovenia
    Anat Histol Embryol 37:408-14. 2008
  8. ncbi Patients attitudes towards experience with use of generics in Slovakia, performance of generic substitution
    M Palagyi
    The Slovak Generic Association GENAS, Bratislava, Slovakia
    Bratisl Lek Listy 109:324-8. 2008
  9. doi Novel inhibitors of beta-ketoacyl-ACP reductase from Escherichia coli
    Katja Kristan
    Drug Discovery, Lek Pharmaceuticals dd, Ljubljana, Slovenia
    Chem Biol Interact 178:310-6. 2009
  10. doi Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits
    Luka Peternel
    Lek Pharmaceuticals d d, Ljubljana, Slovenia
    J Biomol Screen 14:142-50. 2009

Detail Information

Publications38

  1. ncbi The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems
    M D Tricklebank
    Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Essex, UK
    Behav Brain Res 73:15-7. 1996
    ....
  2. ncbi Platelet glycoprotein IIIa gene expression in normal and malignant megakaryopoiesis
    Tanja Ficko
    Lek Pharmaceuticals d d, Biopharmaceuticals, Kolodvorska 27, 1234, Menge, Slovenia
    Ann Hematol 87:131-7. 2008
    ..09 times increase of GPIIIa mRNA in patients was detected. This study is therefore offering the method that could serve as reliable tool for discriminating ET from other similar myeloproliferative disorders...
  3. ncbi Biosimilar somatropin: myths and facts
    W Hoppe
    Sandoz International GmbH, Holzkirchen, Germany
    Horm Res 69:29-30. 2008
  4. pmc Improved determination of plasmid copy number using quantitative real-time PCR for monitoring fermentation processes
    Mihaela Skulj
    Lek Pharmaceuticals d, d, a Sandoz Company, Verovskova 57, SI 1526 Ljubljana, Slovenia
    Microb Cell Fact 7:6. 2008
    ..abstract:..
  5. ncbi Optimization of UDP-N-acetylmuramic acid synthesis
    J Humljan
    Drug Discovery Department, Lek Pharmaceuticals, Verovikova 57, 1526 Ljubljana, Slovenia
    Pharmazie 63:102-6. 2008
    ..An optimization study with the focus on muramyl phosphate and UMP-morpholidate coupling was performed, resulting in a synthetic procedure enabling robust and easily reproducible production on a multi-gram scale...
  6. doi Identification of the heparin-binding domain of TNF-alpha and its use for efficient TNF-alpha purification by heparin-Sepharose affinity chromatography
    Maja Kenig
    Lek Pharmaceuticals d d, Verovskova 57, SI 1526 Ljubljana, Slovenia
    J Chromatogr B Analyt Technol Biomed Life Sci 867:119-25. 2008
    ..With minor modifications, this procedure can be used for TNF-alpha analogues that have full-length N-termini, as shown for the less toxic analogue LK-805...
  7. doi Expression of oestrogen receptor alpha during development of the skeleton in mice fetuses: immunohistochemical study
    E Lovsin Barle
    Institute of Anatomy, Histology and Embryology, Faculty of Veterinary Medicine, University of Ljubljana, Gerbiceva 60, 1000 Ljubljana, Slovenia
    Anat Histol Embryol 37:408-14. 2008
    ..Our findings support the view that ERalpha protein is found in the tissues that undergo bone formation and that ERalpha expression in these tissues shows only minor gender differences in mice fetuses...
  8. ncbi Patients attitudes towards experience with use of generics in Slovakia, performance of generic substitution
    M Palagyi
    The Slovak Generic Association GENAS, Bratislava, Slovakia
    Bratisl Lek Listy 109:324-8. 2008
    ..Generic substitution of branded pharmaceuticals is a widely adopted tool among payers to achieve cost savings. The adoption and safe use of generics among consumers is predicated upon their knowledge of and attitudes toward these products...
  9. doi Novel inhibitors of beta-ketoacyl-ACP reductase from Escherichia coli
    Katja Kristan
    Drug Discovery, Lek Pharmaceuticals dd, Ljubljana, Slovenia
    Chem Biol Interact 178:310-6. 2009
    ..Additionally, a phage-displayed library of random linear 15-mer peptides was screened against FabG, to identify ligands with the common PPLTXY motif...
  10. doi Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits
    Luka Peternel
    Lek Pharmaceuticals d d, Ljubljana, Slovenia
    J Biomol Screen 14:142-50. 2009
    ..The chemical structures of these novel antibacterial hits are disclosed herein...
  11. doi New high-throughput fluorimetric assay for discovering inhibitors of UDP-N-acetylmuramyl-L-alanine: D-glutamate (MurD) ligase
    Katja Kristan
    Drug Discovery, Lek Pharmaceuticals d d, Ljubljana, Slovenia
    J Biomol Screen 14:412-8. 2009
    ..Finally, a novel MurD inhibitor belonging to a new structural class, with an IC50 value of 105 microM, was discovered...
  12. doi Preservation of liquid drug preparations for oral administration
    Stefan Scheler
    Department of Pharmaceutical Technology, Friedrich Schiller University of Jena, Jena, Germany
    J Pharm Sci 99:357-67. 2010
    ..The EP requirement, not less than 1 log(10) reduction from the initial count at 14 days, was only met by preparations with pH 5 and not less than 0.15% sorbic acid...
  13. doi Quantification of live and dead probiotic bacteria in lyophilised product by real-time PCR and by flow cytometry
    Mateja Kramer
    Lek Pharmaceuticals d d, Quality Control, Ljubljana, Slovenia
    Appl Microbiol Biotechnol 84:1137-47. 2009
    ..In conclusion, the PMA real-time PCR and FCM determination of the viability of probiotic bacteria could complement the plate count method which considers only the culturable part of the population...
  14. doi Identification of gentamicin impurities by liquid chromatography tandem mass spectrometry
    Rok Grahek
    Lek Pharmaceuticals d d, Sandoz Development Center Slovenia, Verovskova 57, SI 1526 Ljubljana, Slovenia
    J Pharm Biomed Anal 50:1037-43. 2009
    ..All MS/MS spectra were interpreted and fragmentation transitions for gentamicins and in general for aminoglycoside antibiotics (AG) were proposed. All impurities were identified. More than one isomere were proposed for three impurities...
  15. doi A comparative study of four permanent cannulation procedures in rats
    Luka Peternel
    Lek Pharmaceuticals d d, Verovskova 57, 1529 Ljubljana, Slovenia
    J Pharmacol Toxicol Methods 61:20-6. 2010
    ....
  16. doi Permeability of a novel beta-lactamase inhibitor LK-157 and its ester prodrugs across rat jejunum in vitro
    Petra Iglicar
    Lek Pharmaceuticals d d, Verovskova 57, Ljubljana Sl 1526, Slovenia
    J Pharm Pharmacol 61:1211-8. 2009
    ..This study investigated the permeability of LK-157 and the three ester prodrugs across rat intestine in vitro. The morpholinoethyl ester of sanfetrinem was also investigated...
  17. doi PEGylation of therapeutic proteins
    Simona Jevsevar
    Lek Pharmaceuticals d d, a Sandoz Company, Biopharmaceuticals, Ljubljana, Slovenia
    Biotechnol J 5:113-28. 2010
    ....
  18. doi Lactone pathway to statins utilizing the Wittig reaction. The synthesis of rosuvastatin
    Zdenko Casar
    Lek Pharmaceuticals, D D, Sandoz Development Center Slovenia, API Development, Organic Synthesis Department, Kolodvorska 27, 1234 Menges, Slovenia
    J Org Chem 75:6681-4. 2010
    ..One-pot deprotection and hydrolysis of the resulting 4-O-TBS rosuvastatin lactone provided rosuvastatin in high yield...
  19. ncbi Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents
    Marko Oblak
    Lek Pharmaceuticals, D D, Drug Discovery, Ljubljana, Slovenia
    Curr Med Chem 14:2033-47. 2007
    ..This review summarizes the discovery of ATPase inhibitors of DNA gyrase B in the last decade and their development as potential antibacterial agents...
  20. ncbi Structural and functional characterization of enantiomeric glutamic acid derivatives as potential transition state analogue inhibitors of MurD ligase
    Miha Kotnik
    Lek Pharmaceuticals d d, Drug Discovery, Verovskova 57, 1526 Ljubljana, Slovenia
    J Mol Biol 370:107-15. 2007
    ..The binding modes of N-sulfonyl-D-Glu and N-sulfonyl-L-Glu derivatives were also characterised kinetically. The results of this study represent an excellent starting point for further development of novel inhibitors of this enzyme...
  21. pmc Adenylosuccinate synthetase: site of action of hydantocidin, a microbial phytotoxin
    D L Siehl
    Sandoz Agro, Inc, Research Division, Palo Alto, California 94304 1104, USA
    Plant Physiol 110:753-8. 1996
    ..These results identify the site of action of hydantocidin and establish adenylosuccinate synthetase as an herbicide target of commercial potential...
  22. pmc PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade
    S England
    Sandoz Institute for Medical Research, London, UK
    J Physiol 495:429-40. 1996
    ..7. We propose that the PGE2-mediated increase in excitability in sensory neurones may be due, at least in part, to the cAMP-protein kinase A-dependent modulation of the tetrodotoxin-resistant sodium channel...
  23. ncbi Cyclosporin A inhibits the in vivo production of interleukin-1beta and tumour necrosis factor alpha, but not interleukin-6, by a T-cell-independent mechanism
    J Dawson
    Preclinical Reseacrh, Sandoz Pharma AG, Basel, Switzerland
    Cytokine 8:882-8. 1996
    ..The same mechanism also seems responsible for the inhibition of TNF-alpha production, but not for IL-6, where inhibition by CsA appears to require the presence of T cells...
  24. ncbi The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects
    J Nedelman
    Department of Drug Metabolism and Pharmacokinetics, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    Biopharm Drug Dispos 18:127-38. 1997
    ..05). The drug was well tolerated in both age groups. In particular, greater drug exposure in the elderly did not result in greater toxicity, as indicated by the safety evaluations in the study...
  25. ncbi Suppression of in vivo IgE and tissue IL-4 mRNA induction by SDZ 280.636, a synthetic muramyl dipeptide derivative
    F Kricek
    Sandoz Research Institute, Vienna, Austria
    Immunopharmacology 36:27-39. 1997
    ....
  26. ncbi A tandem solid phase extraction, reversed-phase HPLC method for determining SDZ WAG 994 in dog, monkey and rat blood
    J A Cramer
    Department of Drug Metabolism and Pharmacokinetics, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    J Pharm Biomed Anal 15:749-58. 1997
    ..5 +/- 5.1% and 96.5 +/- 5.0%, respectively. The ruggedness of the method has been demonstrated by multiple analyses, from several toxicokinetic studies, performed by different analysts using comparable instrumentation...
  27. ncbi Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA
    B Wolff
    Sandoz Research Institute, Brunner Strasse 59, A1230 Vienna, Austria
    Chem Biol 4:139-47. 1997
    ..Translocation of Rev from the nucleus to the cytoplasm is essential if Rev is to function. We wanted to identify inhibitors of this transport process because they would be potential antiviral agents...
  28. pmc Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice
    G Weckbecker
    Novartis Pharma Inc, Basel, Switzerland
    Yale J Biol Med 70:549-54. 1997
    ..In summary, the depot formulation SMS pa LAR exerted long-lasting antiproliferative effects in SRIF receptor-negative human pancreatic carcinomas in nude mice...
  29. ncbi Fast analysis of pravastatin in production media
    Andrej Kocijan
    Lek Pharmaceuticals d d, Research and Development, Verovskova 57, SI 1526 Ljubljana, Slovenia
    J Chromatogr B Analyt Technol Biomed Life Sci 822:311-5. 2005
    ..5 mL h(-1). The most sensitive was the method using particle column (LOD was about 10(-5) mg mL(-1)), followed by the system using monolith column (LOD was 2 x 10(-4) mg mL(-1)) and the MECK method (LOD was about 0.02 mg mL(-1))...
  30. ncbi The evaluation of some pharmaceutically acceptable excipients as permeation enhancers for amoxicillin
    Igor Legen
    Lek Pharmaceuticals d d, Research and Development, Verovskova 57, 1526 Ljubljana, Slovenia
    Int J Pharm 308:84-9. 2006
    ..We concluded that sodium lauryl sulfate can be considered as a relatively safe permeation enhancer for amoxicillin in drug delivery systems intended to improve oral bioavailability of this drug...
  31. ncbi Direct thrombin inhibitors built on the azaphenylalanine scaffold provoke degranulation of mast cells
    Luka Peternel
    Drug Discovery, Lek Pharmaceuticals d d, Verovskova 57, 1526 Ljubljana, Slovenia
    Thromb Haemost 95:294-300. 2006
    ..23). LK-732-induced reduction of TAF, the fall of MAP and high mortality originate from LK-732-induced mast cell degranulation. As judged by the SAR study, this effect could be overcome by reducing the basicity of LK-732...
  32. ncbi A membrane-based quantitative carrier test to assess the virucidal activity of disinfectants and persistence of viruses on porous fomites
    Laura Moce-Llivina
    Department of Microbiology, School of Biology, University of Barcelona, Avda Diagonal 645, E 08028 Barcelona, Spain
    J Virol Methods 135:49-55. 2006
    ....
  33. ncbi Asymptotics and bioavailability in a 17-compartment pharmacokinetic model with enterohepatic circulation and remetabolization
    Stefan Horkovics-Kovats
    Clinical Development, Sandoz GmbH, A 6250 Kundl, Austria
    Math Biosci 203:19-36. 2006
    ....
  34. ncbi Inhibition of mast cell degranulation-induced drop of blood pressure with clemastine, cromolyn and compound 48/80 pretreatment
    L Peternel
    Drug Discovery, Lek Pharmaceuticals d d, 1526, Ljubljana, Slovenia
    Inflamm Res 55:S07-8. 2006
  35. ncbi Manufacturing of recombinant therapeutic proteins in microbial systems
    Klaus Graumann
    Novartis Biopharmaceutical Operations, Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria
    Biotechnol J 1:164-86. 2006
    ..This review summarizes current applications and trends for development, production and analytical characterization of recombinant therapeutic proteins in microbial systems...
  36. ncbi Parabrachial nucleus influences the control of normal urinary bladder function and the response to bladder irritation in rats
    Y Liu
    Department of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    Neuroscience 144:731-42. 2007
    ....
  37. ncbi A new amoxicillin/clavulanate therapeutic system: preparation, in vitro and pharmacokinetic evaluation
    Janez Kerc
    Lek Pharmaceuticals d d, Sandoz Development Center Slovenia, Verovskova 57, 1526 Ljubljana, Slovenia
    Int J Pharm 335:106-13. 2007
    ..Prolonged time over MIC of amoxicillin in relation to a regular immediate release amoxicillin/clavulanate formulation was confirmed...
  38. doi New insights into the pore structure of poly(d,l-lactide-co-glycolide) microspheres
    Kerstin Vay
    Sandoz GmbH, Sandoz Development Center Austria, Biochemiestrasse 10, A 6250 Kundl, Austria
    Int J Pharm 402:20-6. 2010
    ..36nm and a macroporous fraction larger than 3.9μm. The total porosity and the ratio between both fractions is controlled by the preparation process and was shown to depend on the solvent extraction temperature...